AU2010268389B2 - Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms - Google Patents
Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms Download PDFInfo
- Publication number
- AU2010268389B2 AU2010268389B2 AU2010268389A AU2010268389A AU2010268389B2 AU 2010268389 B2 AU2010268389 B2 AU 2010268389B2 AU 2010268389 A AU2010268389 A AU 2010268389A AU 2010268389 A AU2010268389 A AU 2010268389A AU 2010268389 B2 AU2010268389 B2 AU 2010268389B2
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- expression
- patient
- macroh2a2
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 130
- 201000011510 cancer Diseases 0.000 title claims abstract description 88
- 238000002405 diagnostic procedure Methods 0.000 title abstract description 5
- 108010034959 macroH2A histone Proteins 0.000 title description 22
- 108010029485 Protein Isoforms Proteins 0.000 title description 18
- 102000001708 Protein Isoforms Human genes 0.000 title description 18
- 230000014509 gene expression Effects 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 61
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 38
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 38
- 201000005202 lung cancer Diseases 0.000 claims abstract description 34
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 24
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 24
- 230000001965 increasing effect Effects 0.000 claims abstract description 15
- 239000012472 biological sample Substances 0.000 claims abstract description 12
- 210000000481 breast Anatomy 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 58
- 239000000523 sample Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 238000003745 diagnosis Methods 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 11
- 210000002381 plasma Anatomy 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 239000013068 control sample Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 238000011532 immunohistochemical staining Methods 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- -1 for example Substances 0.000 claims 4
- 101000898914 Tetrahymena thermophila (strain SB210) Histone H2A.1 Proteins 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 108010033040 Histones Proteins 0.000 description 43
- 230000009758 senescence Effects 0.000 description 26
- 230000035755 proliferation Effects 0.000 description 24
- 102100034528 Core histone macro-H2A.1 Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 239000003550 marker Substances 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 102000001008 Macro domains Human genes 0.000 description 7
- 108050007982 Macro domains Proteins 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 208000037841 lung tumor Diseases 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 208000003200 Adenoma Diseases 0.000 description 6
- 102000006947 Histones Human genes 0.000 description 6
- 239000000032 diagnostic agent Substances 0.000 description 6
- 229940039227 diagnostic agent Drugs 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108010047956 Nucleosomes Proteins 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 210000001623 nucleosome Anatomy 0.000 description 5
- 230000026969 oncogene-induced senescence Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 102100030670 Core histone macro-H2A.2 Human genes 0.000 description 4
- 102100033636 Histone H3.2 Human genes 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 201000005296 lung carcinoma Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 3
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 101710185000 Core histone macro-H2A.2 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000013115 immunohistochemical detection Methods 0.000 description 3
- 201000002037 lung adenoma Diseases 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010034791 Heterochromatin Proteins 0.000 description 2
- 102000017286 Histone H2A Human genes 0.000 description 2
- 108050005231 Histone H2A Proteins 0.000 description 2
- 102100039869 Histone H2B type F-S Human genes 0.000 description 2
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000012093 association test Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000010094 cellular senescence Effects 0.000 description 2
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 210000004458 heterochromatin Anatomy 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008943 replicative senescence Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003375 selectivity assay Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150102326 1.1 gene Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 101150034533 ATIC gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 101710184999 Core histone macro-H2A.1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101001067929 Homo sapiens Core histone macro-H2A.1 Proteins 0.000 description 1
- 101001084697 Homo sapiens Core histone macro-H2A.2 Proteins 0.000 description 1
- 101000842368 Homo sapiens Protein HIRA Proteins 0.000 description 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 102100030473 Protein HIRA Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical class C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- NVGOPFQZYCNLDU-UHFFFAOYSA-N norflurazon Chemical compound O=C1C(Cl)=C(NC)C=NN1C1=CC=CC(C(F)(F)F)=C1 NVGOPFQZYCNLDU-UHFFFAOYSA-N 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09008679.4 | 2009-07-02 | ||
| EP09008679A EP2270510A1 (en) | 2009-07-02 | 2009-07-02 | Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms |
| PCT/EP2010/004008 WO2011000573A1 (en) | 2009-07-02 | 2010-07-02 | Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010268389A2 AU2010268389A2 (en) | 2012-01-12 |
| AU2010268389A1 AU2010268389A1 (en) | 2012-01-19 |
| AU2010268389B2 true AU2010268389B2 (en) | 2014-09-11 |
Family
ID=41100520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010268389A Ceased AU2010268389B2 (en) | 2009-07-02 | 2010-07-02 | Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120171225A1 (OSRAM) |
| EP (2) | EP2270510A1 (OSRAM) |
| JP (1) | JP5792165B2 (OSRAM) |
| CN (1) | CN102472753B (OSRAM) |
| AU (1) | AU2010268389B2 (OSRAM) |
| BR (1) | BRPI1011925A2 (OSRAM) |
| CA (1) | CA2766656A1 (OSRAM) |
| ES (1) | ES2681687T3 (OSRAM) |
| SG (1) | SG177398A1 (OSRAM) |
| WO (1) | WO2011000573A1 (OSRAM) |
| ZA (1) | ZA201109381B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| GB201604806D0 (en) * | 2016-03-22 | 2016-05-04 | Singapore Volition Pte Ltd | Method of identifying a cancer of unknown origin |
| EP3508855A1 (en) * | 2018-01-05 | 2019-07-10 | Allianz Pharmascience Ltd | Method for the selection of patients and kit |
| EP3546944A1 (en) * | 2018-03-30 | 2019-10-02 | Universite d'Aix-Marseille (AMU) | Diagnosis and treatment of a cancer based on the overexpression of the adamtsl5 gene |
| CN108957004B (zh) * | 2018-07-09 | 2021-10-19 | 东南大学 | 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| CN111896740B (zh) * | 2019-05-06 | 2025-02-11 | 山东大学 | 诊断或预测生育缺陷的试剂盒 |
| CN119736252B (zh) * | 2025-01-15 | 2025-06-27 | 首都医科大学 | 组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070148648A1 (en) * | 2003-11-04 | 2007-06-28 | Martin Dugas | Method for distinguishing who classified aml subtypes |
| WO2009030770A2 (en) * | 2007-09-07 | 2009-03-12 | Universite Libre De Bruxelles | Methods and tools for prognosis of cancer in er- patients |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2197915B (en) | 1986-11-19 | 1990-11-14 | Rolls Royce Plc | Improvements in or relating to fluid bearings |
| EP1388734B1 (en) * | 2002-08-01 | 2004-03-03 | MTM Laboratories AG | Method for solution based diagnosis |
| US20020052308A1 (en) * | 1999-03-12 | 2002-05-02 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| US20030190640A1 (en) * | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20030124579A1 (en) * | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| WO2003064474A1 (fr) * | 2002-01-31 | 2003-08-07 | Japan Science And Technology Agency | Production d'un hybridome produisant un anticorps monoclonal dirige contre des peptides de la proteine cenp-a humaine, et methode d'utilisation correspondante |
| CN100480382C (zh) * | 2002-08-16 | 2009-04-22 | 抗癌公司 | 实时测量细胞反应 |
| WO2004063355A2 (en) * | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| EP2251039A3 (en) * | 2003-05-30 | 2010-12-08 | Nippon Shinyaku Co., Ltd. | Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same |
| DE102004037860A1 (de) * | 2004-08-04 | 2006-03-16 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen |
| WO2006119435A2 (en) * | 2005-05-04 | 2006-11-09 | Invitrogen Corporation | Identification of cancer biomarkers and phosphorylated proteins |
| EP1907858A4 (en) * | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| WO2007054814A1 (en) * | 2005-11-14 | 2007-05-18 | Centre National De La Recherche Scientifique - Cnrs | Inhibitors of parp activity and uses thereof |
| EP2145021A2 (en) * | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| JP2008292424A (ja) * | 2007-05-28 | 2008-12-04 | Nippon Medical School | 腫瘍の検出方法 |
| WO2009146545A1 (en) * | 2008-06-05 | 2009-12-10 | University Health Network | Compositions and methods for classifying lung cancer and prognosing lung cancer survival |
-
2009
- 2009-07-02 EP EP09008679A patent/EP2270510A1/en not_active Withdrawn
-
2010
- 2010-07-02 AU AU2010268389A patent/AU2010268389B2/en not_active Ceased
- 2010-07-02 US US13/380,324 patent/US20120171225A1/en not_active Abandoned
- 2010-07-02 WO PCT/EP2010/004008 patent/WO2011000573A1/en not_active Ceased
- 2010-07-02 SG SG2011096849A patent/SG177398A1/en unknown
- 2010-07-02 CA CA2766656A patent/CA2766656A1/en not_active Abandoned
- 2010-07-02 EP EP10730098.0A patent/EP2449383B1/en not_active Not-in-force
- 2010-07-02 BR BRPI1011925A patent/BRPI1011925A2/pt not_active Application Discontinuation
- 2010-07-02 ES ES10730098.0T patent/ES2681687T3/es active Active
- 2010-07-02 CN CN201080029880.5A patent/CN102472753B/zh not_active Expired - Fee Related
- 2010-07-02 JP JP2012518798A patent/JP5792165B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-20 ZA ZA2011/09381A patent/ZA201109381B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070148648A1 (en) * | 2003-11-04 | 2007-06-28 | Martin Dugas | Method for distinguishing who classified aml subtypes |
| WO2009030770A2 (en) * | 2007-09-07 | 2009-03-12 | Universite Libre De Bruxelles | Methods and tools for prognosis of cancer in er- patients |
Non-Patent Citations (2)
| Title |
|---|
| Changolkar, L. N. et al., Molecular and Cellular Biology, 2007, Vol. 27, No. 7, pages 2758-2764 * |
| Pehrson, J. R. et al., Journal of Cellular Biochemistry, 1997, Vol. 65, pages 107-113 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2681687T3 (es) | 2018-09-14 |
| BRPI1011925A2 (pt) | 2017-10-10 |
| CN102472753A (zh) | 2012-05-23 |
| JP5792165B2 (ja) | 2015-10-07 |
| JP2012531612A (ja) | 2012-12-10 |
| ZA201109381B (en) | 2012-08-29 |
| CN102472753B (zh) | 2015-02-11 |
| US20120171225A1 (en) | 2012-07-05 |
| EP2449383A1 (en) | 2012-05-09 |
| EP2270510A1 (en) | 2011-01-05 |
| SG177398A1 (en) | 2012-02-28 |
| AU2010268389A2 (en) | 2012-01-12 |
| EP2449383B1 (en) | 2018-05-16 |
| CA2766656A1 (en) | 2011-01-06 |
| AU2010268389A1 (en) | 2012-01-19 |
| WO2011000573A1 (en) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110053156A1 (en) | Small cell lung carcinoma biomarker panel | |
| KR101976219B1 (ko) | 유방암의 바이오마커 | |
| AU2010268389B2 (en) | Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms | |
| US20110257035A1 (en) | Identification of signature genes associated with hepatocellular carcinoma | |
| KR20180100546A (ko) | Parp 저해제를 이용한 소-세포성 폐암의 치료 방법 | |
| JP5224309B2 (ja) | 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用 | |
| US20120028269A1 (en) | Methods For Detection Of Gastric Cancer | |
| US9005907B2 (en) | Methods and compositions for typing molecular subgroups of medulloblastoma | |
| Hua et al. | LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome | |
| JP7237587B2 (ja) | マーカー、ヒト精巣上体タンパク質４（ｈｅ４）に基づく肺腺癌の再発を検出する方法および関連する使用 | |
| WO2010123124A1 (ja) | 固形がんの再発および予後因子、およびその臨床利用 | |
| ES2896056T3 (es) | PD-ECGF como biomarcador de cáncer | |
| HK1170569B (en) | Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms | |
| HK1170569A (en) | Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms | |
| ES2743508T3 (es) | Métodos y productos para el diagnóstico y el pronóstico de la malignidad de tumores de ovario | |
| KR101825644B1 (ko) | Nedd4-1 단백질의 발현 수준을 측정하는 물질을 포함하는 자궁경부암 진단용 조성물 및 이를 이용한 자궁경부암 진단을 위한 정보제공방법 | |
| WO2019021654A1 (ja) | 膵癌の予後マーカー、膵癌の予後診断キット及び膵癌の予後を予測するための方法 | |
| Sun et al. | Functional screen for secreted proteins by monoclonal antibody library and |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 DEC 2011 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |